Stock Market & Financial Investment News

Evogene announces amendment to Bayer wheat agreementEvogene (EVGN) announced an amendment to the remaining work plan under its collaboration with Bayer CropScience LP (BAYRY) for improved wheat. Pursuant to the amended work plan, Evogene will shift from discovery of additional genes and SNP’s to discovery of novel genomic promoters. Under the amended agreement, Evogene will continue in close teamwork with Bayer to utilize its ATHLETE discovery platform but will shift the focus from the discovery of additional genes and SNP's to identifying novel genomic promoters.

Bayer sees FY15 sales EUR 46The company expects positive currency effects on sales of about 3% compared with the previous year. Bayer plans to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 percent. Bayer aims to increase core earnings per share by a low-teens percentage, allowing for expected positive currency effects of around 3%.